440 Armand-Frappier Boulevard
Suite 300
Laval, QC H7V 4B4
Canada
450 781 0115
https://www.liminalbiosciences.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees:
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Bruce Pritchard BA, CA, FIOD | Chief Exec. Officer | 698.94k | N/A | 1974 |
Mr. Patrick Sartore | Pres | 613.82k | N/A | 1975 |
Dr. Gary J. Bridger Ph.D. | Interim Chief Scientific Officer & Non-Independent Director | 264.69k | N/A | 1963 |
Ms. Marie Iskra L.L.B. | Corp. Sec. & Gen. Counsel | 435.82k | N/A | 1977 |
Ms. N. Nicole Rusaw C.A., C.P.A., CA, CPA, HBACC | Chief Financial Officer | N/A | N/A | 1973 |
Shrinal Inamdar | Mang. of Investor Relations & Communications | N/A | N/A | N/A |
Dr. Steven J. Burton | Pres of Prometic Bioseparations Ltd | N/A | N/A | N/A |
Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
Liminal BioSciences Inc.’s ISS Governance QualityScore as of September 1, 2023 is 8. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 8; Compensation: 10.